Zelgen: Injectable ZG006 included in the list of breakthrough therapy designations

Zelgen's injectable ZG006 has been included in the list of breakthrough therapy varieties published by the National Medical Products Administration's Drug Evaluation Center, indicated for the treatment of patients with advanced small cell lung cancer. The public notice period is from July 9, 2025, to July 16, 2025, with a risk of objections, but it has little impact on the company's recent performance

According to the Zhitong Finance APP, Zelgen (688266.SH) announced that its research product, injectable ZG006, has been included in the list of breakthrough therapy varieties by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The indication is for ZG006 monotherapy in patients with advanced small cell lung cancer who have relapsed or progressed after platinum-based chemotherapy and at least one other systemic treatment (third-line and above)